Bernstein downgraded Tandem Diabetes (TNDM) to Market Perform from Outperform with a price target of $25, down from $35. The firm notes Tandem reported Q4 results Wednesday after market close, and on Thursday the stock dropped 35% to close at $21.75. Bernstein sees four key factors that motivate it to change its view, namely Tandem appeared to lose share of U.S. type 1 new pump starts in Q4, new entrants are intensifying competition for the number 2 spot in the insulin pump market, Tandem announced a U.S. sales expansion/realignment and outside-U.S. distributor transition which could complicate 2025, and margins came in below expectations in Q4, which could stoke anxieties about the company’s path to positive EPS.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target lowered to $53 from $60 at Barclays
- Tandem Diabetes Care: Record Sales and Strategic Growth
- Tandem Diabetes price target lowered to $55 from $65 at RBC Capital
- Tandem Diabetes price target lowered to $33 from $37 at Baird
- Sell Rating for Tandem Diabetes Care Due to Revenue Shortfalls and High Valuation
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue